Your browser is no longer supported. Please, upgrade your browser.
9 Meters Biopharma, Inc.
Index- P/E- EPS (ttm)-0.74 Insider Own1.00% Shs Outstand216.07M Perf Week-4.50%
Market Cap258.06M Forward P/E- EPS next Y-0.15 Insider Trans58.25% Shs Float180.50M Perf Month-35.76%
Income-61.50M PEG- EPS next Q-0.03 Inst Own26.50% Short Float2.40% Perf Quarter-19.70%
Sales- P/S- EPS this Y28.30% Inst Trans106.95% Short Ratio0.53 Perf Half Y43.15%
Book/sh0.20 P/B5.30 EPS next Y6.30% ROA-346.30% Target Price- Perf Year139.49%
Cash/sh0.16 P/C6.81 EPS next 5Y- ROE-936.00% 52W Range0.43 - 2.26 Perf YTD23.40%
Dividend- P/FCF- EPS past 5Y44.30% ROI- 52W High-53.10% Beta-3.94
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low146.51% ATR0.13
Employees12 Current Ratio5.70 Sales Q/Q- Oper. Margin- RSI (14)36.31 Volatility7.08% 9.46%
OptionableYes Debt/Eq0.00 EPS Q/Q87.50% Profit Margin- Rel Volume0.46 Prev Close1.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume8.16M Price1.06
Recom1.70 SMA20-17.77% SMA50-32.07% SMA2006.77% Volume3,784,254 Change-3.64%
Apr-19-21 07:30AM  
Apr-12-21 07:30AM  
Apr-05-21 04:15PM  
Mar-30-21 10:30PM  
Mar-24-21 04:05AM  
Mar-22-21 04:00PM  
Mar-15-21 07:30AM  
Mar-10-21 07:30AM  
Mar-09-21 06:30AM  
Mar-01-21 07:30AM  
Feb-10-21 07:30AM  
Feb-04-21 08:12AM  
Feb-03-21 07:30AM  
Feb-01-21 07:30AM  
Jan-05-21 12:41PM  
Dec-21-20 07:30AM  
Dec-15-20 04:00PM  
Dec-11-20 08:30AM  
Dec-09-20 07:30AM  
Dec-07-20 07:30AM  
Dec-02-20 11:01AM  
Nov-16-20 07:30AM  
Nov-09-20 07:30AM  
Nov-02-20 08:00AM  
Sep-08-20 08:30AM  
Aug-31-20 08:30AM  
Aug-13-20 04:30PM  
Aug-12-20 04:30PM  
Aug-04-20 09:30AM  
Jul-28-20 07:30AM  
Jul-21-20 07:45AM  
Jul-13-20 10:26AM  
Jul-06-20 04:15PM  
Jul-02-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 04:05PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 06:30AM  
May-04-20 05:30PM  
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sirgo Mark ADirectorApr 05Buy1.00300,000300,0001,074,066Apr 06 04:19 PM
Temperato JohnChief Executive OfficerApr 05Buy1.00100,000100,0001,077,522Apr 06 04:16 PM
Sitar Edward JChief Financial OfficerApr 05Buy1.0050,00050,000179,338Apr 06 04:15 PM
Sirgo Mark ADirectorDec 15Buy0.65230,769150,000774,066Dec 17 04:17 PM
Temperato JohnChief Executive OfficerDec 15Buy0.65153,846100,000977,522Dec 17 04:17 PM
Sitar Edward JChief Financial OfficerDec 15Buy0.6561,53840,000129,338Dec 17 04:17 PM
Sirgo Mark ADirectorSep 11Buy0.6521,48514,00421,485Sep 14 08:06 AM
Sirgo Mark ADirectorSep 11Buy0.6877,00052,360538,784Sep 14 08:06 AM
Sirgo Mark ADirectorSep 10Buy0.6050,00030,000461,784Sep 14 08:06 AM
Temperato JohnChief Executive OfficerAug 21Buy0.6970,00048,300615,496Aug 24 07:01 AM
Constantino Michael T.DirectorAug 20Buy0.7534,10825,58134,108Aug 21 04:20 PM
Sirgo Mark ADirectorAug 17Buy0.56100,00056,000411,784Aug 18 05:19 PM
Temperato JohnChief Executive OfficerAug 17Buy0.5735,00019,831545,496Aug 17 04:18 PM